Material Insights · Understanding the Material World

Statins: Overview

What it does

The job the technology does for people, in a short paragraph

Statins lower the LDL cholesterol in the blood that builds up in artery walls, and so cut heart attacks and strokes [1]. Across 14 trials they reduced heart attacks by 25 to 30% [1]. The first was approved in 1987 [1]. In 41 low- and middle-income countries, about 8% of eligible adults used one for primary prevention in surveys from 2013 to 2019 [4].

as of 2026-11-11

How it works

The working principle in plain words, step by step

The body gets cholesterol from food and makes much of its own, mostly in the liver [1, 2]. One step on that production line is run by an enzyme, HMG-CoA reductase, which turns a molecule called HMG-CoA into mevalonate [3]. A statin molecule fits the enzyme and blocks it, so the liver makes less cholesterol [3]. Short of cholesterol, liver cells put more LDL receptors on their surface [2, 3]. These receptors catch LDL particles, the main carriers of cholesterol in the blood, and pull them into the cell [2]. The level of LDL in the blood falls, and less of it is left to form the fatty deposits that narrow blood vessels [1].

as of 2026-11-11

Key figures

The handful of numbers that size it up, each with its unit, year and source

FigureValueUnitYearSource
Fall in LDL cholesterol with simvastatin in the 4S trial35%1994[1]
Fall in coronary heart disease deaths in the 4S trial40%1994[1]
Statin use for primary prevention among eligible adults in 41 low- and middle-income countries8%2019[4]
Statin use for secondary prevention in the same countries21.9%2019[4]
LDL cholesterol lowering with high-intensity statin treatment (more than)50%2024[3]

as of 2026-11-11. The 41-country figures come from surveys carried out between 2013 and 2019 [4]; the year shown is the end of that period. The 4S rows carry 1994, the year the trial results were reported [1]. The high-intensity row carries 2024, the update year of source 3, a publication year, not a data year.

Where it is used

The main places and products the technology is found in

  • Prevention of heart attacks and strokes in people at high risk (primary prevention)
  • Treatment after a heart attack or stroke to prevent another (secondary prevention)
  • Inherited high cholesterol
  • Prescribed in general practice and hospital clinics, taken as daily tablets

as of 2026-11-11

Scale today

How much of it there is now: units in use, made each year and who uses it

Users
An estimated 30 million people worldwide [1, 6]; no newer world count was found
Unit
people taking statins
Year
2008
Note
The 30 million figure appears in the 2008 Lasker award text and again in Endo's 2010 review; 2008 is a publication year, not a data year. Use in poorer countries remains low, about 8% of eligible adults for prevention [4].

as of 2026-11-11

Sources

  1. Statins for lowering LDL and decreasing heart attacks Lasker Foundation (text of the 2008 Lasker-DeBakey Clinical Medical Research Award to Akira Endo), 2008
  2. The Nobel Prize in Physiology or Medicine 1985 - Press release Nobel Assembly at Karolinska Institutet, 1985
  3. Statin Medications StatPearls (NCBI Bookshelf), last updated 29 February 2024, 2024
  4. Use of statins for the prevention of cardiovascular disease in 41 low- and middle-income countries: a cross-sectional study of nationally representative, individual-level data The Lancet Global Health 10(3):e369-e379 (Marcus and others), record at the University of Birmingham, 2022
  5. A historical perspective on the discovery of statins Proceedings of the Japan Academy, Series B 86(5):484-493 (Akira Endo), on PubMed Central, 2010